Tuesday, December 6, 2022
Tuesday, December 6, 2022

    Pfizer profits rocket by 61% to $7.86B as revenue swells 77% due to Covid vaccine and Paxlovid pill – but stock slips as it fails to raise full-year sales forecast

    Your Content is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published.

    Get Your Content. Daily.

    Be the first to know about the biggest stories as they break. Sign up for breaking news email alerts from Your Content.

    COVID-19 vaccine and treatment sales helped Pfizer breeze past Wall Street’s first-quarter expectations, as the drugmaker’s profit grew 61 percent, Your Content has learned.

    Pfizer on Tuesday posted net income of $7.86 billion, up 61% from last year.

    - Advertisement -

    COVID-19 vaccine Comirnatybrought in $13 billion in sales in the quarter.

    Pill treatment Paxlovid, which launched late last year, added another $1.5 billion,‘according to The Daily Mail.

    Your Content for the latest updates. Have a story or news tip? Contact our 24/7 newsroom at 833.336.8013 or e-mail our tip line: [email protected]

    - Advertisement -